UBS raised its price target for the company ahead of the US launch of its Wegovy weight-loss pill. The CEO confirmed strong demand for the pill and stated the company will keep pursuing deals to expand its obesity portfolio. However, the company faces an antitrust lawsuit alleging it suppressed competition for compounded GLP-1 medications. Its stock declined slightly in recent trading, and it is in a competitive race with Eli Lilly to bring an oral obesity drug to market.